These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36996926)

  • 41. Management of Glioblastoma Multiforme in Elderly Patients: A Review of the Literature.
    Halani SH; Babu R; Adamson DC
    World Neurosurg; 2017 Sep; 105():53-62. PubMed ID: 28465276
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of gender on the survival of patients with glioblastoma.
    Tian M; Ma W; Chen Y; Yu Y; Zhu D; Shi J; Zhang Y
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30305382
    [No Abstract]   [Full Text] [Related]  

  • 43. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.
    Neilsen BK; Sleightholm R; McComb R; Ramkissoon SH; Ross JS; Corona RJ; Miller VA; Cooke M; Aizenberg MR
    J Neurooncol; 2019 Mar; 142(1):111-118. PubMed ID: 30535594
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.
    Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M
    J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disparities in health care determine prognosis in newly diagnosed glioblastoma.
    Chandra A; Rick JW; Dalle Ore C; Lau D; Nguyen AT; Carrera D; Bonte A; Molinaro AM; Theodosopoulos PV; McDermott MW; Berger MS; Aghi MK
    Neurosurg Focus; 2018 Jun; 44(6):E16. PubMed ID: 29852776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nuclear respiratory factor 1 transcriptomic signatures as prognostic indicators of recurring aggressive mesenchymal glioblastoma and resistance to therapy in White American females.
    Bhawe K; Das JK; Yoo C; Felty Q; Gong Z; Deoraj A; Liuzzi JP; Ehtesham NZ; Hasnain SE; Singh VP; Mohapatra I; Komotar RJ; Roy D
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1641-1682. PubMed ID: 35441887
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
    Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
    BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular biology of glioma.
    Marumoto T; Saya H
    Adv Exp Med Biol; 2012; 746():2-11. PubMed ID: 22639155
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of long-term survival in patients with glioblastoma multiforme: advancements from the last quarter century.
    Chaudhry NS; Shah AH; Ferraro N; Snelling BM; Bregy A; Madhavan K; Komotar RJ
    Cancer Invest; 2013 Jun; 31(5):287-308. PubMed ID: 23614654
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of Olig2, Nestin, NogoA and AQP4 have no impact on overall survival in IDH-wildtype glioblastoma.
    Behling F; Barrantes-Freer A; Behnes CL; Stockhammer F; Rohde V; Adel-Horowski A; Rodríguez-Villagra OA; Barboza MA; Brück W; Lehmann U; Stadelmann C; Hartmann C
    PLoS One; 2020; 15(3):e0229274. PubMed ID: 32160197
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma.
    Martins EP; Gonçalves CS; Pojo M; Carvalho R; Ribeiro AS; Miranda-Gonçalves V; Taipa R; Pardal F; Pinto AA; Custódia C; Faria CC; Baltazar F; Sousa N; Paredes J; Costa BM
    Mol Oncol; 2022 Jul; 16(14):2611-2631. PubMed ID: 34919784
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemokine receptor CXCR7 is an independent prognostic biomarker in glioblastoma.
    Deng L; Zheng W; Dong X; Liu J; Zhu C; Lu D; Zhang J; Song L; Wang Y; Deng D
    Cancer Biomark; 2017 Jul; 20(1):1-6. PubMed ID: 28759950
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
    Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
    Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.
    Sintupisut N; Liu PL; Yeang CH
    Nucleic Acids Res; 2013 Oct; 41(19):8803-21. PubMed ID: 23907387
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment.
    Alan O; Telli TA; Basoğlu T; Arikan R; Demircan NC; Ercelep O; Bozkurt S; Atasoy BM; Dane F; Yumuk PF
    Clin Neurol Neurosurg; 2020 Sep; 196():105976. PubMed ID: 32531614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma.
    Scheurer ME; Amirian E; Cao Y; Gilbert MR; Aldape KD; Kornguth DG; El-Zein R; Bondy ML
    Clin Cancer Res; 2008 Oct; 14(20):6640-6. PubMed ID: 18927306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.
    Szopa W; Burley TA; Kramer-Marek G; Kaspera W
    Biomed Res Int; 2017; 2017():8013575. PubMed ID: 28316990
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO).
    Leibetseder A; Ackerl M; Flechl B; Wöhrer A; Widhalm G; Dieckmann K; Kreinecker SS; Pichler J; Hainfellner J; Preusser M; Marosi C
    Neuro Oncol; 2013 Jan; 15(1):112-21. PubMed ID: 23223340
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience.
    Alan O; Telli TA; Tuylu TB; Arikan R; Demircan NC; Ercelep O; Kaya S; Babacan NA; Atasoy BM; Bozkurt S; Bayri Y; Gul D; Ekinci G; Ziyal I; Dane F; Yumuk PF
    J Oncol Pharm Pract; 2021 Mar; 27(2):329-339. PubMed ID: 32349641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors of Survival in Turkish Patients with Primary Glioblastoma.
    Bilgin E; Duman BB; Altintas S; Cil T; Gezercan Y; Okten AI
    Turk Neurosurg; 2021; 31(4):641-653. PubMed ID: 33759174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.